DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20191933

Efficacy and safety of ormeloxifene in the management of dysfunctional uterine bleeding

Sabah Malik, Saba Musharaf, Fidah Malik, Mohd Abass

Abstract


Background: The term dysfunctional uterine bleeding (DUB) is used for abnormal uterine bleeding occurring in the absence of identifiable pathology. A number of drugs are available for management of DUB- nonsteroidal anti-inflammatory drugs, tranexamic acid, ethamsylate, hormones like Oral contraceptives progestins etc. The present study was done to determine the efficacy and safety of ormeloxifene in the management of DUB.

Methods: This prospective clinical study involved 50 cases with DUB who were treated with ormeloxifene 60 mg tablet twice a week for first 12 weeks and the once a week for next 12 weeks. They were followed after 6 months of therapy. The outcome was studied by assessment of menstrual blood loss by PBAC score, Hb level in g/dl, endometrial thickness in mm, relief of dysmenorrheal and any side effects of drugs.

Results: The median PBAC score was significantly reduced from 316 to 52 after 6 months of therapy. The mean Hb concentration was significantly increased from 7.8 g/dl to 9.1 g/dl at 6 months of therapy. The mean endometrial thickness was reduced from 10 mm to 7.9 mm after 6 months of therapy. 66% of women showed marked subjective improvement in symptoms. Amenorrhea was the main side effect (12%).

Conclusions: Ormeloxifene has significant effect in reducing endometrial thickness, decreasing the amount of menstrual blood loss, reducing dysmenorrhea and thereby improving the general condition of the patient. It is definitely a better alternative to hysterectomy in women who wish to avoid surgeries and maintain their reproductive functions.


Keywords


Dysfunctional uterine bleeding, Ormeloxifene, SERM

Full Text:

PDF

References


Fraser IS, Critchley HO, Broder M. The FIGO recommendations on terminologies and definition for normal and abnormal uterine bleeding. In: seminars in reproductive medicine: Thieme Medical Publishers. 2011;29:383-90.

Paula J. Benign disease of female reproductive tract. In: Berek JS (editor). Berek and Novak’s gynaecology. Philadelphia: Lippincott Williams and Wilkins; 591-609.

Padubidri BG, Daftary SN. Howkins and Bourne. Shaw’s textbook of gynaecology.16th ed: Elseiver. 2015;333-48.

Speroff L, Fritz MA. Clinical gynaecologic endocrinology and infertility, 8th ed. 591-609.

Frick KD, Clark MA, Steinwachs DM. Financial and quality of life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. Women’s health issues. 2009;19:70-8.

Hallberg L, Hogdahl AM, Nilsson L. Menstrual blood loss- a population study. Variation at different ages and attempts to define normality. Obstet Gynecol Scand.1966;45:320-51.

Gath D, Osborn M, Bungay G. Psychiatric disorder and gynaecological symptoms in middle aged women: A community survey. Br Med J (Clin Res Ed). 1987;294:213-8.

Oehler MK, Rees MC. Menorrhagia: An update. Acta Obstet Gynecol Scand. 2003;82:405-22.

Makker A, Tandon I, Goel MM. Effect of ormiloxifene, a selective estrogen receptor modulator, on biomarkers of endometrial receptivity and pinopode development and its relation to fertility and infertility in Indian subjects. Fertil Steril. 2009;91:2298-307.

Lal J. Clinical pharmacokinetics and interaction of centchroman- a mini review. Contraception. 2010;81:275-80.

Shelly W, Draper MW, Krishnan V. Selective estrogen receptor modulators: An update on recent clinical findings. Obstet Gynecol Surv. 2008;63:163-81.

Higham JM, O’ Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynecol. 1990;734-9.

Biswas SC, Saha SK, Bag TS. Ormeloxifene, a selective estrogen receptor modulator, for treatment of dysfunctional menorrhagia. J Obstet Gynecol. 2004;54:56-9.

Kriplani A, Kulshrestha B, Agarwal N. Efficiency and safety of ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynecol Res 2009;35:746-52.

Bhattacharyya TK, Banerji A. Efficacy of selective estrogen receptor modulator: ‘ormeloxifene’ in management of dysfunctional uterine bleeding. South Asian Federal Obstet Gynecol. 2010;2:207-11.

Agarwal N, Singh S, Agarwal M. Comparative evaluation of the efficacy and safety of ormeloxifene and norethistrone in dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2013;2:194-8.